125 patents
Page 5 of 7
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
18 Nov 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 22 Jul 21
Utility
Systems and Methods for Coordinating Manufacturing of Cells for Patient-specific Immunotherapy
28 Oct 21
A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient.
Anne Brooks, Steve Macrides, Kristin Lanzi
Filed: 22 Apr 21
Utility
Til Expansion from Fine Needle Aspirates and Small Biopsies
7 Oct 21
The present disclosure provides methods for expanding TIL populations from fine needle aspirates (FNAs) or small biopsies which contain low numbers of TILs, using the methods disclosed herein including in a closed system that leads to improved phenotype and increased metabolic health of the TILs in a shorter time period.
Michelle Simpson-Abelson, Cecile Chartier-Courtaud
Filed: 18 May 21
Utility
Expansion of TILs from Cryopreserved Tumor Samples
9 Sep 21
In some embodiments, methods of expanding tumor infiltrating lymphocytes from cryopreserved tumor tissue and methods of using the expanded tumor infiltrating lymphocytes in the treatment of human diseases, including cancers, are disclosed In some embodiments, compositions of cryopreserved tumor tissues are disclosed.
Anand Veerapathran, Kenneth Onimus
Filed: 10 Feb 21
Utility
Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes
26 Aug 21
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 16 Apr 21
Utility
Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes
19 Aug 21
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 16 Apr 21
Utility
Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes
19 Aug 21
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 16 Apr 21
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
15 Jul 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender
Filed: 12 Jan 21
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
8 Jul 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender
Filed: 13 Jan 21
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
8 Jul 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender
Filed: 13 Jan 21
Utility
Remnant Tumor Infiltrating Lymphocytes and Methods of Preparing and Using the Same
24 Jun 21
In some embodiments, methods of delivering a therapeutically effective amount of an expanded number of tumor infiltrating lymphocytes obtained from tumor remnants to a patient in need thereof, for the treatment of a cancer, are disclosed.
Michelle R. Simpson-Abelson, Christopher Mosychuk, Michael T. Lotze
Filed: 19 Feb 21
Utility
Expansion of Tumor Infiltrating Lymphocytes (Tils) with Tumor Necrosis Factor Receptor Superfamily (TNFRSF) Agonists and Therapeutic Combinations of Tils and TNFRSF Agonists
24 Jun 21
Methods of expanding tumor infiltrating lymphocytes (TILs) using a tumor necrosis factor receptor superfamily (TNFRSF) agonist, such as a 4-1BB agonist, a CD27 agonist, a glucocorticoid-induced TNF receptor-related agonist, an OX40 agonist, a HVEM agonist, or a CD95 agonist, and uses of such expanded TILs in the treatment of diseases such as cancer are disclosed herein.
Michael T. Lotze, Krit Ritthipichai
Filed: 9 Mar 21
Utility
Methods of Using Tumor Infiltrating Lymphocytes In Double-refractory Melanoma
20 May 21
Methods of treating melanomas refractory to other therapies using tumor infiltrating lymphocytes are disclosed.
Maria Fardis
Filed: 5 Jun 18
Utility
Expansion of Tumor Infiltrating Lymphocytes (Tils) with Adenosine A2A Receptor Antagonists and Therapeutic Combinations of Tils and Adenosine A2A Receptor Antagonists
13 May 21
Methods of expanding tumor infiltrating lymphocytes (TILs) in the presence of an adenosine A2A receptor (A2aR) antagonist, such as vipadenant, CPI-444 (ciforadenant), SCH58261, SYN115, ZM241385, SCH420814, a xanthine superfamily A2aR antagonist, or related adenosine receptor 2A antagonist, and uses of expanded TILs in the treatment of diseases such as cancer are disclosed herein.
Maria Fardis
Filed: 12 Feb 19
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
13 May 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 18 Dec 20
Utility
Closed Process for Expansion and Gene Editing of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
6 May 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Cecile Chartier-Courtaud, Krit Ritthipichai
Filed: 26 Apr 19
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
6 May 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 18 Dec 20
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
6 May 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 18 Dec 20
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
6 May 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 12 Jan 21
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
6 May 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 12 Jan 21